"Dinoprostone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The most common and most biologically active of the mammalian prostaglandins. It exhibits most biological activities characteristic of prostaglandins and has been used extensively as an oxytocic agent. The compound also displays a protective effect on the intestinal mucosa.
| Descriptor ID |
D015232
|
| MeSH Number(s) |
D10.251.355.255.550.250.200 D23.469.050.175.725.250.200
|
| Concept/Terms |
Dinoprostone- Dinoprostone
- PGE2 alpha
- alpha, PGE2
- Prostaglandin E2alpha
- E2alpha, Prostaglandin
- Prostaglandin E2
- E2, Prostaglandin
- Prostaglandin E2 alpha
- E2 alpha, Prostaglandin
- alpha, Prostaglandin E2
- PGE2
- PGE2alpha
|
Below are MeSH descriptors whose meaning is more general than "Dinoprostone".
Below are MeSH descriptors whose meaning is more specific than "Dinoprostone".
This graph shows the total number of publications written about "Dinoprostone" by people in this website by year, and whether "Dinoprostone" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 2 | 2 | 4 |
| 1999 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 1 | 2 |
| 2003 | 0 | 3 | 3 |
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 2 | 3 |
| 2009 | 1 | 1 | 2 |
| 2010 | 1 | 0 | 1 |
| 2011 | 0 | 2 | 2 |
| 2014 | 1 | 2 | 3 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 2 | 2 |
| 2018 | 0 | 1 | 1 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 0 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dinoprostone" by people in Profiles.
-
Apoptosis in mesenchymal stromal cells activates an immunosuppressive secretome predicting clinical response in Crohn's disease. Mol Ther. 2023 Dec 06; 31(12):3531-3544.
-
Prostaglandin E2 amplifies IL-17 production by ?d T cells during barrier inflammation. Cell Rep. 2021 07 27; 36(4):109456.
-
EP2 Receptor Blockade Attenuates COX-2 Upregulation During Intestinal Inflammation. Shock. 2020 09; 54(3):394-401.
-
PTGES/PGE2 signaling links immunosuppression and lung metastasis in Gprc5a-knockout mouse model. Oncogene. 2020 04; 39(15):3179-3194.
-
6,8-di-C-glycosyl flavones with ß-furanoarabinose from Scutellaria baicalensis and their anti-inflammatory activities. Nat Prod Res. 2019 May; 33(9):1243-1250.
-
Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance). J Clin Oncol. 2017 Jul 01; 35(19):2184-2192.
-
Role of Cyclooxygenase-2 on Intermittent Hypoxia-Induced Lung Tumor Malignancy in a Mouse Model of Sleep Apnea. Sci Rep. 2017 03 16; 7:44693.
-
Autophagy gene ATG7 regulates ultraviolet radiation-induced inflammation and skin tumorigenesis. Autophagy. 2017; 13(12):2086-2103.
-
Insights into the structure activity relationship of mPGES-1 inhibitors: Hints for better inhibitor design. Int J Biol Macromol. 2016 Jul; 88:624-32.
-
Loss of diacylglycerol kinase epsilon in mice causes endothelial distress and impairs glomerular Cox-2 and PGE2 production. Am J Physiol Renal Physiol. 2016 05 01; 310(9):F895-908.